|
Fig. 2 Amylovis-201 attenuated the hyperlocomotor response of 5 dpfwfs1abKO mutant zebrafish larvae in the VMR test through σ1 agonism: (a) VMR activity profiles of V-treated wfs1abWTand wfs1abKO mutant lines and wfs1abKO zebrafish treated with Amylovis-201 at 3 μmol/L; (b) dose–response effect of Amylovis-201 on the zebrafish mobility; and (c) effect of NE-100. The fish mobility was measured for 70 min, with 30 min of training in the dark (OFF), then 2 cycles of light/dark (ON/OFF) of 10 min each. In (b, c), the distance traveled by wfs1abWT and wfs1abKO larvae during the light/dark cycle was averaged as differences between the OFF and ON phases. Data show mean ± SEM of the number of animals indicated below the columns. Two-way ANOVAs: F(1,162) = 0.4218, P = 0.5170 for the genotype, F(3,162) = 1.316, P = 0.2710 for the treatment, F(3,162) = 5.561, P = 0.0012 for the interaction in (b); F(1,163) = 9.608, P = 0.0023 for the genotype, F(3,63) = 6.781, P = 0.0002 for the treatment, F(3,163) = 1.616, P = 0.1876 for the interaction in (c). ∗P < 0.05 vs. V-treated wfs1abWT zebrafish; #P < 0.05, ###P < 0.001 vs. V-treated wfs1abKO zebrafish; Dunnet's test.